Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Trial details
- Registry ID
- NCT00482092
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Adult Human Mesenchymal Stem Cells; Adult human mesenchymal stem cells; Remestemcel-L
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseNCT00482092 | Mesoblast, Inc. | Phase 3 | Completed | 2014-09-15Actual |
| Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)NCT00877903 | Mesoblast, Inc. | Phase 2 | Completed | 2011-05-18Actual |
| Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseNCT01233960 | Mesoblast, Inc. | Phase 3 | Completed | 2014-09-15Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |